A Phase 2, Randomized, Open Label Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Subjects With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3

Trial Profile

A Phase 2, Randomized, Open Label Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Subjects With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3

Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2017

At a glance

  • Drugs Selonsertib (Primary) ; Simtuzumab (Primary)
  • Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 09 May 2017 Results assessing correlations between hepatic PDFF with histologic measures of steatosis, presented at the Digestive Disease Week 2017
    • 14 Nov 2016 Results presented at The Liver Meeting 2016, as per the Gilead Sciences media release.
    • 14 Nov 2016 Results published in the Gilead Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top